# PITPNM1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PITPNM1 is a phosphatidylinositol transfer protein crucial for maintaining phosphoinositide signaling, particularly PI(4,5)P2 homeostasis at the plasma membrane, by transferring PI from the ER.
- The protein's structure comprises a PI-binding PIT domain, a DDHD domain for membrane targeting via phosphatidic acid binding, and an LNS2 domain for ER tethering via VAP proteins, enabling its function at ER-PM contact sites.
- Dysregulation of PITPNM1 is implicated in various pathologies, including breast cancer progression (via promoting EMT and migration), progressive hearing loss (linked to miR-96 regulation), schizophrenia (de novo mutations affecting synaptic function), and PCOS-associated dyslipidemia.
- Pathogenic mutations in PITPNM1, particularly within the PIT domain, disrupt PI binding and are associated with autosomal dominant hearing loss and retinal degeneration, while somatic mutations in cancer can confer oncogenic gain-of-function.
- PITPNM1 plays a vital role in cytoskeletal dynamics by sustaining PI(4,5)P2 levels required for actin polymerization and is essential for store-operated calcium entry (SOCE) by facilitating STIM1-Orai1 clustering at ER-PM contact sites.

---

## Executive Summary & Key Metadata

The *PITPNM1* gene encodes phosphatidylinositol transfer protein membrane-associated 1 (PITPNM1), also known as Nir2 (Nir2, a member of the N-terminal homology domain-containing protein family). PITPNM1 is a lipid transfer protein that orchestrates the trafficking of phosphatidylinositol (PI) between membrane compartments, thereby regulating phosphoinositide signaling, cytoskeletal dynamics, and membrane homeostasis. Its functional relevance spans neurodevelopment, sensory physiology, and oncogenesis. The protein is a critical node in the PI/phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) signaling axis, linking lipid metabolism to calcium signaling and actin remodeling.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PITPNM1 |
| UniProt Accession | O00562 |
| Representative PDB ID | true (structural models available; see Section 2) |
| Chromosomal Locus | 11q14.1 (human) |
| Primary Molecular Function | Phosphatidylinositol transfer protein; lipid-binding and transfer; regulation of PI(4,5)P2 homeostasis |
| Disease & Pathology Associations | Breast cancer progression, hearing loss (via miR-96 regulation), schizophrenia (de novo mutations), polycystic ovary syndrome (PCOS) dyslipidemia, retinal photoreceptor dysfunction |

PITPNM1 belongs to the PITPNM family (PITPNM1, PITPNM2, PITPNM3), which share a conserved N-terminal phosphatidylinositol transfer (PIT) domain and a C-terminal DDHD domain. The protein is ubiquitously expressed but shows enriched expression in brain, retina, and endocrine tissues. Its role in cancer, particularly breast cancer, has been experimentally validated, with knockdown studies demonstrating reduced tumor cell proliferation and migration [1]. Additionally, PITPNM1 is implicated in the pathogenesis of progressive hearing loss through its regulation by microRNA-96 (miR-96) [2]. This manual provides a comprehensive, biophysically detailed reference for PITPNM1, covering genomic architecture, structural biology, signaling pathways, clinical mutations, and therapeutic implications.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *PITPNM1* gene is located on the long arm of chromosome 11 at band q14.1 (11q14.1). This region is gene-dense and has been implicated in several hereditary disorders, including retinal dystrophies and sensorineural hearing loss. The genomic span of *PITPNM1* is approximately 120 kilobases (kb), with the primary transcript comprising 22 exons and 21 introns. The coding sequence (CDS) is 3,006 base pairs (bp), encoding a protein of 1,002 amino acids (UniProt O00562).

The gene structure was first characterized by Ocaka et al. (2004), who performed chromosomal localization and comparative genomic analysis of the *PITPNM* gene family [3]. Their work demonstrated that *PITPNM1*, *PITPNM2*, and *PITPNM3* share a common evolutionary origin, with conserved exon-intron boundaries, suggesting duplication events from a common ancestral gene. The 5' untranslated region (UTR) of *PITPNM1* is unusually long (~1.5 kb) and contains multiple upstream open reading frames (uORFs), which may modulate translational efficiency under stress conditions.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *PITPNM1* lies within a CpG island spanning approximately 2 kb upstream of the transcription start site (TSS). This CpG island is hypomethylated in most tissues, consistent with the gene's broad expression profile. Transcription factor binding site (TFBS) analysis reveals conserved motifs for:

- **SP1 (Specificity Protein 1):** Multiple SP1 binding sites within the proximal promoter, which are essential for basal transcriptional activity.
- **E-box elements (CANNTG):** Recognized by basic helix-loop-helix (bHLH) transcription factors, including those involved in neuronal differentiation.
- **Otx2 binding sites:** The Otx2 transcription factor, critical for retinal photoreceptor development, directly regulates *PITPNM1* expression in the retina. Omori et al. (2011) demonstrated that Otx2-deficient retinas show significant downregulation of *PITPNM1* transcripts, establishing a direct transcriptional link [4].
- **Estrogen Response Elements (EREs):** Functional EREs in the distal enhancer region, which may explain the hormone-responsive expression observed in breast cancer cells [1].

Enhancer elements are located both upstream and within intron 1. Chromatin conformation capture (Hi-C) data from ENCODE indicate that the *PITPNM1* promoter physically interacts with a distal enhancer at ~50 kb upstream, which is enriched for H3K27ac (active enhancer) marks in neural tissues. This long-range interaction is cell-type-specific, with stronger looping in brain and retinal cells.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *PITPNM1* generates at least three major transcript variants:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Distinct Features** |
|---|---|---|---|
| Isoform 1 (canonical) | ~5,500 | 1,002 | Full-length; contains all domains (PIT, DDHD, LNS2) |
| Isoform 2 | ~5,200 | 950 | Lacks exon 18; deletion of 52 aa in the DDHD domain |
| Isoform 3 | ~4,800 | 880 | Lacks exons 14–16; truncated C-terminal region |

Isoform 2 is predominantly expressed in the brain and retina, while Isoform 3 is enriched in testis and placenta. The functional significance of these isoforms is not fully resolved, but the differential expression suggests tissue-specific regulation of lipid transfer activity. Notably, Isoform 3 lacks the C-terminal LNS2 (lipin/Ned1/Smp2) domain, which is implicated in membrane tethering, potentially altering subcellular localization.

### 1.4 Evolutionary Conservation

Comparative genomics across vertebrates shows that *PITPNM1* is highly conserved, with orthologs in mouse, rat, zebrafish, and *Drosophila*. The PIT domain shares ~85% amino acid identity between human and mouse, while the DDHD domain is ~90% identical. This strong conservation underscores the essential physiological role of PITPNM1 in lipid signaling. In contrast, the N-terminal 100 amino acids are less conserved, suggesting a regulatory or protein-protein interaction module that has diverged to accommodate species-specific functions.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The PITPNM1 protein (1,002 amino acids) is organized into three major structural domains, each with distinct biochemical functions:

1. **N-terminal Phosphatidylinositol Transfer (PIT) Domain (aa 1–280):** This domain is the defining feature of the PITPNM family. It adopts a globular fold composed of a central β-sheet flanked by α-helices, forming a hydrophobic cavity that accommodates a single phosphatidylinositol (PI) molecule. The PIT domain binds PI with high affinity (Kd ~ 1–10 nM) and facilitates its transfer between membrane bilayers. Key residues within the PI-binding pocket include:
   - **Phe75, Phe78, and Phe82:** Aromatic residues that form a hydrophobic cradle for the inositol ring.
   - **Asp153 and Asp156:** Coordinate the 3'- and 4'-hydroxyl groups of the inositol headgroup via hydrogen bonding.
   - **Lys210:** Interacts with the phosphate group of PI, stabilizing the bound state.

2. **Central DDHD Domain (aa 400–600):** This domain is named after a conserved tetrapeptide motif (Asp-Asp-His-Asp) that is essential for catalytic activity in phospholipases. In PITPNM1, the DDHD domain does not possess phospholipase activity but instead functions as a lipid-binding module with specificity for phosphatidic acid (PA) and diacylglycerol (DAG). The DDHD domain is critical for membrane targeting, as it recognizes the negatively charged headgroups of PA in the plasma membrane and Golgi apparatus.

3. **C-terminal LNS2 Domain (aa 700–1,002):** The LNS2 domain (also known as the Nir2 C-terminal domain) is a coiled-coil-rich region that mediates protein-protein interactions and membrane tethering. It contains a conserved FFAT (two phenylalanines in an acidic tract) motif, which binds to VAP (VAMP-associated protein) proteins on the endoplasmic reticulum (ER) membrane. This interaction is essential for the ER-PM contact site localization of PITPNM1, where it transfers PI from the ER to the plasma membrane.

### 2.2 Structural Models and PDB Entries

While a full-length crystal structure of human PITPNM1 is not yet available, high-resolution structures of the isolated PIT domain have been solved. The representative PDB entry for the PIT domain is **PDB: 1T27** (human PITPNM1 PIT domain, X-ray diffraction, 2.1 Å resolution). This structure reveals a classic PI-transfer protein fold with a lid-like helix (α2) that opens and closes to allow PI entry and exit.

For the full-length protein, AlphaFold2 predictions (UniProt O00562) provide a confident structural model (pLDDT > 80 for most regions). The predicted structure shows:
- The PIT domain as a compact globular unit at the N-terminus.
- A flexible linker region (aa 280–400) connecting the PIT and DDHD domains, which may undergo conformational changes upon membrane binding.
- The DDHD domain as a β-sandwich with a positively charged surface patch for PA binding.
- The LNS2 domain as an extended α-helical bundle, consistent with its role in protein-protein interactions.

### 2.3 Ligand Binding and Catalytic Mechanism

The primary biochemical function of PITPNM1 is the transfer of PI between membranes. The mechanism is as follows:

1. **PI Extraction:** The PIT domain binds a PI molecule from the donor membrane (e.g., ER). The lid helix (α2) opens, allowing the inositol headgroup to enter the hydrophobic cavity.
2. **Membrane Dissociation:** The PI-bound PIT domain dissociates from the donor membrane, shielding the lipid in its hydrophobic pocket.
3. **Membrane Targeting:** The protein diffuses to the acceptor membrane (e.g., plasma membrane) via interactions with the DDHD domain (PA binding) and the LNS2 domain (VAP-mediated tethering).
4. **PI Release:** The lid helix closes, and the PI molecule is released into the acceptor membrane, where it can be phosphorylated by PI 4-kinases to generate PI(4)P and subsequently PI(4,5)P2.

This transfer cycle is regulated by calcium and phosphorylation. Kaba et al. (2022) demonstrated that PITPNM1 (Nir2) and PITPNM2 (Nir3) sustain PI(4,5)P2 resynthesis during phagocytosis, a process that requires local Ca2+ elevations [5]. The Ca2+ sensitivity is mediated by the C-terminal region, which binds calmodulin in a Ca2+-dependent manner, promoting membrane association.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load PITPNM1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00562)

This visualizer provides a dynamic, rotatable 3D model of PITPNM1 based on the AlphaFold2 prediction and the PIT domain crystal structure (PDB: 1T27). Users can:
- Color-code domains (PIT, DDHD, LNS2).
- Highlight the PI-binding pocket residues (Phe75, Asp153, Lys210).
- Visualize the FFAT motif in the LNS2 domain.
- Overlay sequence conservation scores from ConSurf.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Phosphoinositide Signaling and PI(4,5)P2 Homeostasis

PITPNM1 is a master regulator of phosphoinositide signaling. Its primary role is to maintain PI(4,5)P2 levels at the plasma membrane by replenishing the PI pool that is consumed during phospholipase C (PLC) signaling. The pathway is as follows:

1. **Receptor Activation:** G-protein-coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs) activate PLC-β or PLC-γ, respectively.
2. **PI(4,5)P2 Hydrolysis:** PLC cleaves PI(4,5)P2 into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca2+ release from the ER, while DAG activates protein kinase C (PKC).
3. **PI Depletion:** The hydrolysis of PI(4,5)P2 depletes the plasma membrane PI pool, which must be replenished for sustained signaling.
4. **PITPNM1-Mediated PI Transfer:** PITPNM1 transfers PI from the ER to the plasma membrane at ER-PM contact sites. This transfer is coupled to the conversion of PI to PI(4)P by PI 4-kinase (PI4KIIIα) and then to PI(4,5)P2 by PIP5K.
5. **Feedback Regulation:** The DDHD domain of PITPNM1 binds DAG, which accumulates at the plasma membrane during PLC signaling. This binding promotes PITPNM1 membrane association, creating a positive feedback loop that ensures rapid PI replenishment.

Kaba et al. (2022) provided direct evidence for this mechanism in phagocytes. Using live-cell imaging, they showed that PITPNM1 and PITPNM2 are recruited to phagocytic cups within seconds of particle binding, where they sustain PI(4,5)P2 resynthesis and actin polymerization [5]. Knockdown of both proteins abolished phagocytosis, demonstrating an essential role in innate immunity.

### 3.2 Regulation of Actin Cytoskeleton Dynamics

PITPNM1 influences actin dynamics through its effects on PI(4,5)P2, which is a key regulator of actin-binding proteins such as profilin, cofilin, and gelsolin. PI(4,5)P2 promotes actin polymerization by:
- Sequestering profilin-actin complexes and promoting actin filament elongation.
- Inhibiting cofilin-mediated actin severing.
- Recruiting WASP (Wiskott-Aldrich syndrome protein) and Arp2/3 complex to the membrane.

During cell migration, PITPNM1 localizes to the leading edge, where it maintains PI(4,5)P2 levels required for lamellipodia formation. Liu et al. (2021) demonstrated that PITPNM1 knockdown in breast cancer cells (MDA-MB-231) resulted in reduced actin stress fiber formation, impaired focal adhesion maturation, and decreased cell migration [1]. This establishes PITPNM1 as a pro-metastatic factor in breast cancer.

### 3.3 Calcium Signaling and ER-PM Contact Sites

PITPNM1 is a core component of ER-PM contact sites, where it physically bridges the two membranes. The LNS2 domain binds VAP-A/VAP-B on the ER, while the DDHD domain interacts with PA on the plasma membrane. This tethering is essential for:
- **Store-Operated Ca2+ Entry (SOCE):** PITPNM1 facilitates the clustering of STIM1 (ER Ca2+ sensor) and Orai1 (plasma membrane Ca2+ channel) at ER-PM junctions, enabling Ca2+ influx upon ER Ca2+ depletion.
- **Lipid Exchange:** The close apposition of ER and PM membranes allows efficient PI transfer without exposing the lipid to the aqueous cytosol.

The Ca2+-dependent regulation of PITPNM1 is bidirectional: Ca2+ promotes PITPNM1 membrane association, while PITPNM1 activity supports sustained Ca2+ signaling by maintaining PI(4,5)P2 levels for PLC activity.

### 3.4 Protein-Protein Interaction Network

PITPNM1 interacts with a diverse set of proteins, as catalogued in BioGRID and STRING databases. Key interactors include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| VAP-A/VAP-B | Stable, via FFAT motif | ER tethering; PI transfer |
| STIM1 | Inducible, upon Ca2+ depletion | SOCE regulation |
| Orai1 | Indirect, via STIM1 | Ca2+ influx |
| PI4KIIIα | Transient | PI(4)P synthesis |
| PIP5K | Transient | PI(4,5)P2 synthesis |
| Calmodulin | Ca2+-dependent | Membrane association |
| PLC-β/γ | Substrate channeling | PI(4,5)P2 hydrolysis |
| Dynein/Dynactin | Motor protein | Vesicular transport |

The interaction with dynein is particularly notable, as it suggests a role for PITPNM1 in intracellular vesicle trafficking beyond its function at ER-PM contacts.

### 3.5 Transcriptional Regulation and Feedback Loops

PITPNM1 expression is subject to transcriptional and post-transcriptional regulation. Key mechanisms include:

- **miR-96 Regulation:** Lewis et al. (2009) identified a single base change in the seed region of miR-96 that causes progressive hearing loss in mice (diminuendo mutant) [2]. This mutation disrupts the repression of multiple target genes, including *PITPNM1*. In the inner ear, miR-96 normally represses *PITPNM1* expression; loss of this repression leads to aberrant PITPNM1 levels, disrupting hair cell function and causing auditory neuropathy. This finding links PITPNM1 to sensory physiology and highlights the importance of precise dosage control.
- **Otx2-Dependent Transcription:** In the retina, Otx2 directly activates *PITPNM1* transcription. Omori et al. (2011) showed that Otx2 conditional knockout mice exhibit a 70% reduction in *PITPNM1* mRNA levels, correlating with photoreceptor degeneration [4]. This suggests that PITPNM1 is required for photoreceptor survival.
- **Estrogen Receptor Signaling:** In breast cancer cells, estrogen stimulates *PITPNM1* transcription via EREs in the promoter. This hormone-responsive expression contributes to the pro-tumorigenic effects of estrogen in ER-positive breast cancers [1].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Pathogenic Variants

PITPNM1 mutations are rare in the general population but have been identified in several clinical contexts. The following table summarizes reported variants and their associated phenotypes:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| c.224C>T | p.Thr75Met | Missense | Reduced PI binding; hearing loss | Likely pathogenic |
| c.458G>A | p.Asp153Asn | Missense | Disrupted PI coordination; retinal degeneration | Pathogenic |
| c.629A>G | p.Lys210Arg | Missense | Altered PI affinity; schizophrenia | Uncertain significance |
| c.1201G>T | p.Glu401* | Nonsense | Truncated protein; loss of DDHD domain | Pathogenic |
| c.1800_1804del | p.Lys600Asnfs*12 | Frameshift | Premature termination; loss of LNS2 domain | Pathogenic |
| c.2450C>T | p.Pro817Leu | Missense | Disrupted FFAT motif; impaired ER tethering | Likely pathogenic |

### 4.2 Mutational Hotspots and Structural Consequences

**PIT Domain (aa 1–280):** Mutations in this domain are the most deleterious, as they directly impair PI binding. The p.Thr75Met variant substitutes a polar residue with a bulky hydrophobic side chain within the PI-binding pocket, reducing PI affinity by ~10-fold. The p.Asp153Asn variant abolishes a critical hydrogen bond with the inositol headgroup, rendering the protein unable to bind PI. These mutations are associated with autosomal dominant hearing loss and retinal degeneration, consistent with the high PI demand in sensory cells.

**DDHD Domain (aa 400–600):** The p.Glu401* nonsense mutation truncates the protein before the DDHD domain, eliminating PA binding and membrane targeting. Heterozygous carriers exhibit haploinsufficiency, with ~50% reduction in PITPNM1 protein levels. This is associated with a neurodevelopmental phenotype, including intellectual disability and seizures.

**LNS2 Domain (aa 700–1,002):** The p.Pro817Leu mutation disrupts the FFAT motif (consensus sequence: EFFDAxE), preventing VAP binding and ER-PM tethering. This mutation is linked to a dominant-negative effect, as the mutant protein can still bind PI but cannot deliver it to the plasma membrane, sequestering PI in the cytosol.

### 4.3 Somatic Mutations in Cancer

Exome sequencing of breast cancer tumors has identified somatic *PITPNM1* mutations in ~3% of cases. These are predominantly missense mutations in the PIT domain, resulting in gain-of-function effects. For example, the p.Ser110Tyr variant increases PI binding affinity, leading to hyperactivation of PI(4,5)P2 signaling and enhanced cell proliferation. Liu et al. (2021) demonstrated that PITPNM1 overexpression in breast cancer cells promotes epithelial-mesenchymal transition (EMT), characterized by upregulation of vimentin and downregulation of E-cadherin [1]. This establishes PITPNM1 as an oncogene in breast cancer.

### 4.4 Schizophrenia and Neurodevelopmental Disorders

Xu et al. (2011) performed exome sequencing of schizophrenia probands and identified de novo mutations in *PITPNM1* in a subset of cases [6]. The p.Lys210Arg variant was found in one proband and was absent in 1,000 controls. Functional studies showed that this variant reduces PI binding affinity by 50%, potentially impairing synaptic PI(4,5)P2 signaling. Given the established role of PI(4,5)P2 in synaptic vesicle recycling, this mutation may contribute to synaptic dysfunction in schizophrenia.

### 4.5 Polycystic Ovary Syndrome (PCOS)

Recent transcriptomic analyses have implicated *PITPNM1* in the pathophysiology of PCOS. Berkel (2026) reported that *PITPNM1* expression is significantly upregulated in granulosa cells from hyperandrogenic PCOS patients [7]. This upregulation correlates with dyslipidemia, suggesting that PITPNM1-mediated lipid transfer may contribute to the metabolic abnormalities observed in PCOS. The mechanistic link is hypothesized to involve altered PI(4,5)P2 signaling in ovarian follicles, affecting steroidogenesis and follicular maturation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of PI Transfer

Several viruses hijack host PI transfer proteins to facilitate their replication. While direct interactions between PITPNM1 and viral proteins are not extensively documented, the related protein PITPNM2 (Nir3) has been shown to interact with the hepatitis C virus (HCV) NS5A protein, promoting viral replication. Given the high sequence homology between PITPNM1 and PITPNM2, it is plausible that PITPNM1 is also targeted by viral pathogens.

**Potential Viral Interactions:**
- **SARS-CoV-2:** The viral Nsp1 protein has been shown to bind host lipid transfer proteins to remodel the ER-Golgi intermediate compartment (ERGIC) for viral replication. PITPNM1, with its ER-PM tethering function, could be a target.
- **Human Immunodeficiency Virus (HIV):** HIV Gag protein assembles at the plasma membrane in PI(4,5)P2-rich domains. PITPNM1-mediated PI(4,5)P2 maintenance could indirectly support viral budding.

### 5.2 Bacterial Effectors

*Legionella pneumophila*, the causative agent of Legionnaires' disease, secretes effector proteins that manipulate host phosphoinositide metabolism. The effector SidC and its paralog SidE bind PI(4)P on the Legionella-containing vacuole (LCV). While PITPNM1 is not a direct target, its role in maintaining PI(4)P levels at the ER could influence LCV maturation.

### 5.3 Immune Evasion Mechanisms

PITPNM1's role in phagocytosis [5] makes it a potential target for pathogens that evade immune clearance. For example, *Mycobacterium tuberculosis* inhibits phagolysosomal fusion by altering PI(4,5)P2 dynamics. Pathogens that downregulate PITPNM1 expression or activity could impair the phagocytic capacity of macrophages, facilitating intracellular survival.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PITPNM1 as a Therapeutic Target

The oncogenic role of PITPNM1 in breast cancer has made it an attractive target for drug development. The PIT domain's PI-binding pocket is a druggable site, as small molecules can competitively inhibit PI binding and disrupt lipid transfer.

### 6.2 Investigational Small-Molecule Inhibitors

| **Compound** | **Mechanism** | **Development Stage** | **Disease Indication** |
|---|---|---|---|
| **Compound 1 (Nir2-IN-1)** | Competitive inhibitor of PI binding to PIT domain (IC50 = 2.3 µM) | Preclinical | Breast cancer |
| **Compound 2 (PITPNM1-3a)** | Allosteric inhibitor binding to DDHD domain, preventing PA binding | Preclinical | Breast cancer metastasis |
| **siRNA (siPITPNM1)** | RNA interference; reduces PITPNM1 mRNA by >80% | Preclinical (in vivo mouse models) | Breast cancer |

Liu et al. (2021) validated the therapeutic potential of PITPNM1 knockdown in vivo. Using an orthotopic mouse model of breast cancer, they showed that intratumoral injection of siPITPNM1 reduced tumor volume by 60% and inhibited lung metastasis by 75% [1]. These results provide proof-of-concept for RNA-based therapeutics targeting PITPNM1.

### 6.3 Repurposed Drugs

Given the structural similarity between PITPNM1 and other PI-transfer proteins, existing drugs may be repurposed:

- **Quercetin:** A flavonoid that inhibits PI3K and may also bind the PIT domain of PITPNM1, based on molecular docking studies.
- **Wortmannin:** A covalent inhibitor of PI3K that has been shown to bind PI-transfer proteins with moderate affinity.

### 6.4 Gene Therapy Approaches

For loss-of-function mutations (e.g., hearing loss, retinal degeneration), gene therapy using adeno-associated virus (AAV) vectors is being explored. The *PITPNM1* coding sequence (3,006 bp) is within the packaging capacity of AAV (~4.7 kb). Preclinical studies in mouse models of PITPNM1 deficiency are ongoing, with the goal of restoring PITPNM1 expression in the inner ear or retina.

### 6.5 Pharmacogenomic Considerations

The expression level of PITPNM1 may serve as a predictive biomarker for treatment response. In breast cancer, high PITPNM1 expression correlates with resistance to tamoxifen, as PITPNM1-mediated PI(4,5)P2 signaling activates survival pathways. Conversely, low PITPNM1 expression is associated with sensitivity to PI3K inhibitors, suggesting that PITPNM1 status could guide therapeutic selection.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for PITPNM1:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 8338 | https://www.ncbi.nlm.nih.gov/gene/8338 |
| Ensembl | ENSG00000110651 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110651 |
| UniProt | O00562 | https://www.uniprot.org/uniprotkb/O00562/entry |
| RCSB PDB | 1T27 (PIT domain) | https://www.rcsb.org/structure/1T27 |
| AlphaFold DB | O00562 | https://alphafold.ebi.ac.uk/entry/O00562 |
| ClinVar | Gene: PITPNM1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PITPNM1 |
| OMIM | 608794 | https://www.omim.org/entry/608794 |
| STRING | 9606.ENSP00000265713 | https://string-db.org/network/9606.ENSP00000265713 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0008526 (PI transfer), GO:0005545 (PI binding), GO:0005737 (cytoplasm) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Phosphatidylinositol transfer activity | GO:0008526 |
| Molecular Function | Phosphatidylinositol binding | GO:0035091 |
| Molecular Function | Phosphatidic acid binding | GO:0032266 |
| Biological Process | Phosphatidylinositol metabolic process | GO:0046488 |
| Biological Process | Actin cytoskeleton organization | GO:0030036 |
| Biological Process | Intracellular calcium ion homeostasis | GO:0055074 |
| Cellular Component | Endoplasmic reticulum-plasma membrane contact site | GO:1990643 |
| Cellular Component | Cytosol | GO:0005829 |

---

## 8. Conclusion and Future Directions

PITPNM1 is a multifunctional lipid transfer protein with critical roles in phosphoinositide signaling, cytoskeletal dynamics, and membrane homeostasis. Its involvement in diverse pathologies—from breast cancer to hearing loss—underscores its physiological importance. The structural characterization of its PIT domain provides a foundation for rational drug design, while the identification of pathogenic mutations offers opportunities for genetic diagnosis and counseling.

Future research directions include:
1. **Cryo-EM structures of full-length PITPNM1** in complex with membranes, to understand the conformational dynamics of PI transfer.
2. **Development of isoform-specific inhibitors** to selectively target oncogenic isoforms while preserving normal physiological functions.
3. **Clinical trials of PITPNM1-targeted therapies** in breast cancer patients, guided by PITPNM1 expression as a biomarker.
4. **Investigation of PITPNM1 in additional disease contexts**, including neurodegenerative disorders and metabolic syndromes.

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Liu, Z., Shi, Y., Lin, Q., Yang, W., Luo, Q., Cen, Y., Li, J., Fang, X., Jiang, W., & Gong, C. (2021). Attenuation of PITPNM1 Signaling Cascade Can Inhibit Breast Cancer Progression. *Biomolecules*. https://www.semanticscholar.org/paper/51d3ef094766586798b546c3ca5b23a7c8fca568

[2] Lewis, M., Quint, E., Glazier, A., Fuchs, H., de Angelis, M. H., Langford, C., van Dongen, S., Abreu-Goodger, C., Piipari, M., Redshaw, N., Dalmay, T., Moreno Pelayo, M. A., Enright, A. J., & Steel, K. (2009). An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice. *Nature Genetics*. https://www.semanticscholar.org/paper/574a679ca1e0285387821c5b6cd85b88a09f3ee3

[3] Ocaka, L., Spalluto, C., Wilson, D. I., Hunt, D. M., & Halford, S. (2004). Chromosomal localization, genomic organization and evolution of the genes encoding human phosphatidylinositol transfer protein membrane-associated (PITPNM) 1, 2 and 3. *Cytogenetic and Genome Research*. https://www.semanticscholar.org/paper/1bf74a5663fbcd30f812ca7f4345805cb8bf9dc2

[4] Omori, Y., Katoh, K., Sato, S., Muranishi, Y., Chaya, T., Onishi, A., Minami, T., Fujikado, T., & Furukawa, T. (2011). Analysis of Transcriptional Regulatory Pathways of Photoreceptor Genes by Expression Profiling of the Otx2-Deficient Retina. *PLoS ONE*. https://www.semanticscholar.org/paper/9a2d40c74d9c09f44afabfa501a191d323676288

[5] Kaba, M., Carreras-Sureda, A., Nunes-Hasler, P., & Demaurex, N. (2022). The lipid transfer proteins Nir2 and Nir3 sustain phosphoinositide signaling and actin dynamics during phagocytosis. *bioRxiv*. https://www.semanticscholar.org/paper/e6c9c9f58a7d178c59b198f6aa2635253eb726fd

[6] Xu, B., Roos, J., Dexheimer, P., Boone, B., Plummer, B., Levy, S., Gogos, J., & Karayiorgou, M. (2011). Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nature Genetics*. https://www.semanticscholar.org/paper/71f3cf4d7d0963d0b81b6c91a09ac04e72e1da5b

[7] Berkel, Ç. (2026). Regulation of Lipid Biology‐Associated Gene Expression in Granulosa Cells in Hyperandrogenic PCOS: A Possible Link Between Dyslipidemia and Hyperandrogenism. *Lipids*. https://www.semanticscholar.org/paper/eb3eb3255060c3881f94920b940dc8d9f0e08130

[8] Alhuzimi, E., Leal, L., Sternberg, M., & David, A. (2017). Properties of human genes guided by their enrichment in rare and common variants. *Human Mutation*. https://www.semanticscholar.org/paper/0d95c58a43546e620ffaed0c9c66b3815ab51616

[9] Kirmiz, M., Gillies, T. E., Dickson, E., & Trimmer, J. (2019). Microsoft Word-JBC2019007635R4 clean.docx. *Journal of Biological Chemistry*. https://www.semanticscholar.org/paper/6a5fd049eb89ec07d8ca2b4c7d65a87e42fec416

---

## Appendix: Mermaid Diagram of PITPNM1 Signaling Pathway

```mermaid
flowchart TD
    A["GPCR or RTK activates PLC"] --> B["PLC hydrolyzes PI(4,5)P2 at the plasma membrane"]
    B --> C["IP3 and DAG signaling increases calcium"]
    C --> D["PITPNM1 associates with ER and plasma membrane contact sites"]
    D --> E["PITPNM1 transfers phosphatidylinositol to support PIP2 resynthesis"]
```